ELVN Enliven Therapeutics Inc

Price (delayed)

$35.71

Market cap

$2.17B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.67

Enterprise value

$2.04B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 10
Highlights
The company's quick ratio has surged by 90% YoY and by 41% QoQ
ELVN's equity has soared by 57% YoY
The company's net income rose by 4.7% QoQ but it fell by 4.2% YoY

Key stats

What are the main financial stats of ELVN

ELVN stock price

How has the Enliven Therapeutics stock price performed over time
Intraday
-0.89%
1 week
-12.15%
1 month
-14.18%
1 year
60.21%
YTD
131.88%
QTD
-8.9%

Financial performance

How have Enliven Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$115.79M
Net income
-$98.78M
Gross margin
N/A
Net margin
N/A
The company's net income rose by 4.7% QoQ but it fell by 4.2% YoY
Enliven Therapeutics's operating income has decreased by 5% YoY but it has increased by 3.2% QoQ

Price vs fundamentals

How does ELVN's price correlate with its fundamentals

Growth

What is Enliven Therapeutics's growth rate over time

Valuation

What is Enliven Therapeutics stock price valuation
P/E
N/A
P/B
4.71
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Enliven Therapeutics's EPS has increased by 13% YoY and by 9% QoQ
ELVN's P/B is 107% above its 5-year quarterly average of 2.3 and 64% above its last 4 quarters average of 2.9
ELVN's equity has soared by 57% YoY

Efficiency

How efficient is Enliven Therapeutics business performance
ELVN's return on invested capital is up by 44% year-on-year and by 14% since the previous quarter
The return on equity is up by 34% year-on-year and by 13% since the previous quarter
Enliven Therapeutics's ROA has increased by 32% YoY and by 13% from the previous quarter

Dividends

What is ELVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ELVN.

Financial health

How did Enliven Therapeutics financials performed over time
The current ratio has soared by 91% YoY and by 41% from the previous quarter
The company's quick ratio has surged by 90% YoY and by 41% QoQ
The debt is 100% less than the equity
ELVN's equity has soared by 57% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.